Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model

Cancer Research

Volumn 60, Issue 24, 2000, Pages 6995-7001

  Schreurs, Marco W J ^a   Eggert, Andreas A O ^a   De Boer, Annemiek J ^a   Vissers, Joost L M ^a   Van Hall, Thorbald ^b   Offringa, Rienk ^b   Figdor, Carl G ^a   Adema, Gosse J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIFFERENTIATION ANTIGEN; EPITOPE; FREUND ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE DERIVATIVE; TUMOR ANTIGEN; TUMOR VACCINE; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER MODEL; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DEPIGMENTATION; IMMUNOLOGICAL TOLERANCE; MALE; MELANOCYTE; MELANOMA; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMIUM; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITOPES; GENES, MHC CLASS I; HUMANS; INHIBITORY CONCENTRATION 50; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MELANOCYTES; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDES; PLASMIDS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0034671292     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Human tumor antigens for cancer vaccine development
2. Molecular and immunological characterization of melanocyte lineage-specific antigens
3. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides
4. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection
5. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
6. Heteroclitic immunization induces tumor immunity
7. gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive tumoricidal T cells using high-affinity, altered peptide ligand
8. Coupling and uncoupling of tumor immunity and autoimmunity
9. Dendritic cells: Unique leukocyte populations which control the primary immune response
10. Dendritic cell-based vaccines: From mouse mode s to clinical cancer immunotherapy
11. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
12. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2)
13. Selection of successive tumour lines for metastasis
14. A cloned, immortal line of murine melanoblasts inducible to differentiate to melanocytes
15. A line of non-tumorigenic mouse melanocytes, syngeneic with the B 16 melanoma and requiring a tumour promoter for growth
16. Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes
17. Empty MHC class I molecules come out in the cold
18. An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301
19. Generation of large numbers of dendritic cells from mouse borne marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
20. Suppression of human colorectal carcinoma cell growth by wild-type p53
21. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLAA2.1-transfected melanomas
22. Identification of T-cell epitopes: Rapid isolation of class I-presented peptides from viable cells by mild acid elution
23. Identification of a graft versus host disease-associated human minor histocompatibility antigen
24. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes
25. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100
26. A second tyrosinase-related protein, TRP2, maps to and is mutated at the mouse slaty locus
27. Cloning, expression and tissue distribution of the murine homologue of the melanocyte lineage-specific antigen gp100
28. Tumor immunity and autoimmunity induced by immunization with homologous DNA
29. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
30. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
31. Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides
32. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
33. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo
34. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
35. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma